摘要:目的: 分析特非那定所致不良反應的臨床特征、相關因素,為臨床藥物治療中藥品不良反應的防治提供參考依據。 方法 :檢索1986～2008年國內文獻源特非那定的不良反應資料,并加以分析研究。 結果 :34例不良反應報告中女性明顯多于男性;不良反應以心血管系統損害最多(23例,占6766%),其次為皮膚及附件損害(5例,1470%);不良反應預后較好。 結論 :患者的性別、體質、合并用藥等因素能影響不良反應的發生,對于引起心律失常不良反應臨床應提高警惕,減少不良反應的發生。Abstract: Objective: To analyze the clinical features、correlation factors of ADRs caused by Terfenadine drugs and provide beneficial references for preventing and curing the ADRs. Methods :To collect and analyze the cases of ADRs caused by Terfenadine from medical journals of 19862008 Results :Women were more than men in 34 ADRs;cardiovascular system lesions accounted for 6766%,skin and its appendix lesions accounted for 1470%;ADRs prognosis well. Conclusion :The occurrence of ADRs caused by Terfenadine due to many factors such as sex、age and combination drug,ect. The ADRs caused by second generation antihistamine drugs must be reconstred.
ObjectiveIt has been reported that many different kinds of antiepileptic drugs (AEDs) induced cutaneous adverse drug reactions (cADRs) are associated with human leukocyte antigen (HLA) genes. However, previous studies mainly focused on the traditional AEDs. There are very few research focused on the new AEDs, especially levetiracetam (LEV). This study aimed to evaluate the clinical characteristics of LEV-induced cADRs and to explore its possible genetic association with the HLA alleles. MethodsNine cases with LEV-induced cADRsfrom September 2011 to December 2014 were recruited. Demographic and clinical information of these cases was summarized. Additionally, cases were matched with LEV-tolerant controls (1 : 4).High-resolution HLA-A, -B, -DRB1 genotyping were performed for each subject. The allele frequencies between the cases and controls were compared. ResultsNine cases with LEV-induced cADRs formed the LEV-cADRs group. And 36 epilepsy patients who had received or have been receiving LEV treatment for at least 3 months without any adverse drug reactions formed the LEV-tolerant controls group. All LEV-induced cADRs were mild skin rashes whichoccurred within 30 days of LEV exposure. The mean latency from LEV exposure to skin rash was (15.67±5.41) days (ranging 6~27). Two patients in the LEV-cADRs group carried the HLA-DRB1*0405allele, while none subjects in the control group carried this allele. The carrier rate of HLA-DRB1*0405 allele between the LEV-cADRs group and control group was statistical significant [P=0.036, OR=13.875, 95%CI(1.273, 151.230)]. ConclusionsSafety monitoring was necessary within four weeks after the initiation of LEV treatment, although it has been regarded as a safe AED.Our study suggested thatHLA-DRB1*0405 allele may be a risk factor for LEV-induced cADRs. However, the Further studies with large samples are needed to clarify this hypothesis and the genetic and immunological mechanisms of LEV-induced cADRs should also be further explored in the future.